Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AbbVie, AstraZeneca and Merck Sharpe & Dohme LLC
Description:
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone
marrow that affects older adults. CLL is the most common type of
leukemia in adults. It affects B cell lymphocytes, which originate
in the bone marrow, develop in the lymph nodes, and normally fight
infection by producing antibodies. In 2022, it is expected that
there will be 20,160 new cases of CLL and about 4,410 deaths, which
represents an increase in both numbers. Patients with CLL are often
diagnosed when they are asymptomatic; therefore, knowing when to
initiate treatment may pose a challenge to clinicians. Furthermore,
patients with CLL have impaired immune systems and multiple
comorbidities, which can complicate management and impact treatment
decisions. Fortunately for patients with CLL, several new treatments
have recently become available giving clinicians many new options to
improve patient outcomes with these new treatments and strategies.
New combination regimens have recently become available that have
shown the ability to greatly improve outcomes in previously
untreated CLL. This activity focuses on these evolving options,
outlines how to incorporate quality measures for the diagnosis and
management of CLL, and describes how to apply evidence-based data to
select appropriate treatment regimens and manage toxicities.
Upon completion of this
activity, participants will be able to:
-
Examine the clinical and economic
burden of chronic lymphocytic leukemia (CLL), including factors
that contribute to poor prognosis and increased costs
-
Discuss the molecular
pathophysiology associated with the development of CLL, the role
of the B-cell receptor (BCR) pathway, and the rationale for
therapeutically targeting this pathway
-
Compare and contrast recent safety
and efficacy data on BTK inhibitors, and especially their
combinations, in CLL
-
Evaluate the latest clinical CLL
guideline recommendations for selection and sequencing of
therapy, individualized to the patient, including mutation
status, performance status, comorbidities, and patient
preferences
-
Differentiate the safety profiles
for BTK inhibitors and their combinations as well as monitoring
and management strategies to mitigate adverse effects
-
Analyze the cost drivers associated
with the management of CLL and the value of evolving treatment
approaches in lowering cost of care and healthcare utilization
|
Faculty: |
John N. Allan, MD
Assistant Professor of Medicine
Weill Cornell Medicine |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Allan has served as a consultant for Abbvie,
AstraZeneca, Beigene, Epizyme, Genentech, JanssAbbvie,
AstraZeneca, Beigene, Epizyme, Genentech, Janssen,
Pharmacyclics, and TG Therapeutics. He has served on the
speaker's bureau for Abbvie, AstraZeneca, BeiGene,
JAbbvie, AstraZeneca, BeiGene, Janssen, and
Pharmacyclics. He has received grant/research support
from BeiGene, Celgene, Genentech, Janssen, and TG
Therapeutics. His presentation has been reviewed for any
bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
AbbVie, AstraZeneca and Merck Sharpe & Dohme LLC
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |